[1] |
XIE Rui, GENG Zihan, BAO Lei, ZHAO Ronghua, LI Shuran, SUN Qiyue, WANG Xinwei, ZHANG Jingsheng, CUI Xiaolan, GUO Shanshan, SUN Jing.
Research Progress in Pharmacological Actions, Mechanisms, Structural Modifications and Targeted Formulations of Ribavirin
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 950-955.
|
[2] |
LIU Ming, ZHENG Li, ZHANG Weina, SUN Xuelin, TIAN Jinhui, ZHAO Yan.
Research Progress in Biological Activity and Mechanisms of Pachymic Acid
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 826-830.
|
[3] |
ZHONG Xinru, YANG Deying, GUAN Tangming, CHEN Ju, JIANG Dongbo.
Research Progress in Adverse Reactions Caused by Obinutuzumab in the Treatment of Follicular Lymphoma
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 831-835.
|
[4] |
YE Ling, LIU Xiaoying, DANG Xuefei, LI Xuelian, LI Gang.
Research Progress in Drugs for Brain Metastases from Advanced Breast Cancer
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 714-720.
|
[5] |
LI Can, LIU Lehuan, CHEN Xia, QU Jianbo.
Pharmacy of Chinese Medicine Compound Preparations Based on Human Experiences
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 564-569.
|
[6] |
ZHU Zhipeng, LYU Qiang, YE Xiaofei, GUO Xiaojing.
Disproportionality of Adverse Events to KRAS G12C Inhibitors Based on the FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 297-304.
|
[7] |
MIN Qiong, LI Peng, DAI Xiaoyan, FAN Chunling, YOU Haisheng.
One Case of Neurotoxicity Caused by Fluorouracil Injection in a Patient with Metastatic Colorectal Cancer
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 346-348.
|
[8] |
NIE Xiaolu, SUN Feng, YAN Aixia, PENG Xiaoxia, ZHAN Siyan.
Methodology for Constructing Benchmark Database of Adverse Drug Reactions Based on Multi-Source Information
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 10-15.
|
[9] |
LI Wenlong, JIA Juanjuan, HUANG Haiwei, YAO Jing, ZHANG Chunqing, WANG Yan, ZHANG Hui.
Developments and Prospects of Radiopharmaceuticals in China
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 37-42.
|
[10] |
HOU Tiantian, WANG Xudong, YANG Ping, ZHOU Pengbo, QIN Chao, HUANG Ying, WANG Ailing, GENG Xingchao, ZHOU Xiaobing, LIU Defang.
Biodistribution of Therapeutic DNA Vaccines in Mice
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 58-66.
|
[11] |
WANG Yijin, TANG Jing, YANG Chao, XU Kai, ZHANG Mengdie, GAO Jian, WU Xiaoli, ZHANG Yue, NIU Xiaobing, JIANG Hesong, MAO Fei, ZHOU Shan, JIANG Xi, GUO Zhongying, SUN Su'an, XU Ming, XU Zongyuan, WANG Hengbing, LI Xin, FU Guangbo.
Clinical research of submucosal low-dose gemcitabine injection combined with transurethral resection of bladder tumor in the treatment of medium-high risk non-muscle invasive bladder cancer
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1044-1050.
|
[12] |
LIU Tianrui, LI Yao, CHEN Yuxin, LI Hui, GAO Haiyun, YUAN Yuan.
Toxicity analysis and safe application of 7 common fungi prone to adverse reactions
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 489-495.
|
[13] |
GAO Haiyun, CHEN Yuxin, LI Yao, LI Hui, LIU Tianrui, YUAN Yuan.
Herbal textual research and adverse reaction study of Coprinus comatus
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 502-506.
|
[14] |
LI Wenpeng, LIU Mingyu, CAO Ying, ZHOU Huziwei, WANG Shengfeng.
Supervision status and research progress of global abuse of opioids
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 513-518.
|
[15] |
LIU Yi, GENG Ying, QIN Ling, GUO Xianhui, CHEN Hua, PEI Yusheng.
Research routes of hygroscopicity of chemical reference substances
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 280-282.
|